Loading...
XNAS
VIVS
Market cap344kUSD
Oct 08, Last price  
0.18USD
1D
-7.47%
1Q
-79.84%
Jan 2017
-99.98%
IPO
-99.98%
Name

Organovo Holdings Inc

Chart & performance

D1W1MN
XNAS:VIVS chart
P/E
—
P/S
2.43
EPS
—
Div yield, %
—
Shrs. gr., 5y
35.10%
Rev. gr., 5y
-42.01%
Revenues
131k
-9.03%
001,197,0001,197,000379,000571,0001,483,0004,230,0004,603,0003,091,0002,196,00001,500,000370,000109,000144,000131,000
Net income
-14m
L+456.39%
-147,817-147,817-43,553,000-43,553,000-25,848,000-30,082,000-38,575,000-38,447,000-34,803,000-26,635,000-18,710,000-16,826,000-11,448,000-17,259,000-14,671,000-2,488,000-13,843,000
CFO
-11m
L+14.44%
-109,425-109,425-9,693,000-9,693,000-15,561,000-19,601,000-29,368,000-29,185,000-28,857,000-20,375,000-14,882,000-13,323,000-8,453,000-12,408,000-14,653,000-9,461,000-10,827,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Organovo Holdings, Inc. is a biotechnology firm that specializes in engineering sophisticated 3D tissues designed to accurately mimic critical facets of human diseases. Central to its operations is a comprehensive 3D human tissue platform, which features the company's proprietary NovoGen Bioprinters. These automated devices are crucial for fabricating complex, living 3D tissues from mammalian cells. The platform also includes supporting technologies necessary for creating specialized "bio-inks" and for the bioprinting of multi-cellular tissues with intricate structures. Organovo supplies specific products, such as ExVive human liver tissue and ExVive human kidney tissue, which are employed for predictive preclinical evaluation of investigational drug compounds. The company was founded in 2007 and maintains its corporate headquarters in Solana Beach, California.

Key people

Kirk Malloy
Independent Chairman of the Board · since 2017
Taylor J. Crouch
Director, Chief Executive Officer and President · since 2017
Jennifer Kinsbruner Bush
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary · since 2017
Sharon Presnell
Chief Scientific Officer · since 2016
Paul Gallant
General Manager · since 2015
Steven Hughes
Chief Medical Officer · since 2018
Carolyn Beaver
Independent Director · since 2019
Mark Kessel
Independent Director · since 2016
David M. Shapiro
Independent Director · since 2018
URL
https://organovo.com/
IPO date
Aug 02, 2013
Employees
15
Domiciled in
US
Incorporated in
US
Headquarters & legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT